Stock Market Live May 6, 2026: S&P 500 (SPY) Up on End-of-War Hopes Again

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Lee Jackson | Jul 16, 2016 at 9:15 AM EDT

Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now

With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great…

Trey Thoelcke | Jul 14, 2016 at 12:20 PM EDT

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and…

Chris Lange | Jul 13, 2016 at 10:55 AM EDT

Why the Teva Acquisition Proves It Is a Stock to Own for the Decade

Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector…

Chris Lange | Jul 13, 2016 at 9:15 AM EDT

Short Sellers Run for Cover From Major Pharma

The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | Jul 13, 2016 at 8:10 AM EDT

Short Sellers Become More Selective on Major Biotechs

The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in…

Chris Lange | Jul 12, 2016 at 11:35 AM EDT

CytRx Crumbles on Late-Stage Whiff

CytRx absolutely crumbled in Tuesday’s session after the company released less than favorable late-stage results.

Chris Lange | Jul 12, 2016 at 11:10 AM EDT

Shire Gains Key FDA Approval in Dry Eye Treatment

Shire made waves Tuesday morning following a key FDA approval of its eye drop solution indicated for the treatment of…

Chris Lange | Jul 12, 2016 at 10:25 AM EDT

Protagonist Therapeutics Files for IPO

Protagonist Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Chris Lange | Jul 12, 2016 at 10:10 AM EDT

Biotechs With Drug Pipelines Closest to Zero Valuation

Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline…

Chris Lange | Jul 12, 2016 at 8:35 AM EDT

Sage Therapeutics Scores Huge Win in Depression Trial

Sage Therapeutics blew out expectations early on Tuesday morning after the company released results from its mid-stage depression trial.

Trey Thoelcke | Jul 12, 2016 at 6:40 AM EDT

Is Too Big to Fail Coming to a Health Care Sector Near You?

The fact that major health care mergers were announced at the same time that the Affordable Care Act began to…

Chris Lange | Jul 11, 2016 at 12:40 PM EDT

Patheon Prepares for IPO With Updated Pricing Details

Patheon expects to price more than 30 million shares in the range of $19 to $22 per share for a…

Chris Lange | Jul 11, 2016 at 11:20 AM EDT

Audentes Gears Up for IPO With Updated Pricing

Audentes Therapeutics expects to price its 5 million shares in the range of $14 to $16, for an initial public…

Chris Lange | Jul 10, 2016 at 9:50 AM EDT

How Badly Analysts Ditched Juno Therapeutics After Clinical Hold

Juno Therapeutics saw its shares sink on Friday after the U.S. Food and Drug Administration levied a clinical hold on…

Douglas A. McIntyre | Jul 9, 2016 at 9:25 AM EDT

Viagra Price Drops 50% as Drug Faces Competition

Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.

1 … 202 203 204 205 206 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

Why the Teva Acquisition Proves It Is a Stock to Own for the Decade

Short Sellers Run for Cover From Major Pharma

Short Sellers Become More Selective on Major Biotechs

CytRx Crumbles on Late-Stage Whiff

Shire Gains Key FDA Approval in Dry Eye Treatment

Protagonist Therapeutics Files for IPO

Biotechs With Drug Pipelines Closest to Zero Valuation

Sage Therapeutics Scores Huge Win in Depression Trial

Is Too Big to Fail Coming to a Health Care Sector Near You?

Patheon Prepares for IPO With Updated Pricing Details

Audentes Gears Up for IPO With Updated Pricing

How Badly Analysts Ditched Juno Therapeutics After Clinical Hold

Viagra Price Drops 50% as Drug Faces Competition

Stock Market Live May 6, 2026: S&P 500 (SPY) Up on End-of-War Hopes Again

Live Nasdaq Composite: Bulls Keep Control on Tech Deals, Chip Profit Growth and Easing Oil

Oracle’s $553 Billion Backlog Is Larger Than the GDP of Most Countries. It Also Grew 325% in a Year

If You Want to Beat the Market, Start With These 3 Stocks

US Foods Rebound From Pandemic Years Continues to Reward Investors

How PayPal Survived When They Knew the Exact Hour Their $200 Million Would Hit Zero

How a Roth Conversion at 64 Added $1,116 to a Retiree's Medicare Premiums Two Years Later

How PayPal Survived When They Knew the Exact Hour Their $200 Million Would Hit Zero

Oracle’s $553 Billion Backlog Is Larger Than the GDP of Most Countries. It Also Grew 325% in a Year

Health and Healthcare Articles

All Health and Healthcare Articles

Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

Why the Teva Acquisition Proves It Is a Stock to Own for the Decade

Short Sellers Run for Cover From Major Pharma

Short Sellers Become More Selective on Major Biotechs

CytRx Crumbles on Late-Stage Whiff

Shire Gains Key FDA Approval in Dry Eye Treatment

Protagonist Therapeutics Files for IPO

Biotechs With Drug Pipelines Closest to Zero Valuation

Sage Therapeutics Scores Huge Win in Depression Trial

Is Too Big to Fail Coming to a Health Care Sector Near You?

Patheon Prepares for IPO With Updated Pricing Details

Audentes Gears Up for IPO With Updated Pricing

How Badly Analysts Ditched Juno Therapeutics After Clinical Hold

Viagra Price Drops 50% as Drug Faces Competition

Stock Market Live May 6, 2026: S&P 500 (SPY) Up on End-of-War Hopes Again

Live Nasdaq Composite: Bulls Keep Control on Tech Deals, Chip Profit Growth and Easing Oil

Oracle’s $553 Billion Backlog Is Larger Than the GDP of Most Countries. It Also Grew 325% in a Year

If You Want to Beat the Market, Start With These 3 Stocks

US Foods Rebound From Pandemic Years Continues to Reward Investors

Featured Reads

How PayPal Survived When They Knew the Exact Hour Their $200 Million Would Hit Zero

How a Roth Conversion at 64 Added $1,116 to a Retiree's Medicare Premiums Two Years Later